Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.

Merck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the first week of 2024.

Merck is a pharmaceutical giant whose medications and vaccines play key roles in the fight against viruses, cancer, and cardiovascular diseases. On October 26, 2023, Merck published results for the...

Merck MRK, +0.18% is in talks to buy cancer drugmaker Harpoon Therapeutics HARP, -1.49% for about $700 million, or $23 per share, Bloomberg News reported, citing people familiar with the matter. Me...

Merck & Co's Chief Executive Officer Robert Davis said on Thursday the company is seeking GLP-1 treatments with benefits beyond weight loss.

In the latest trading session, Merck (MRK) closed at $114.77, marking a +1.35% move from the previous day.

The Weekly MDA Breakouts completed the best year since this model was released on Seeking Alpha in 2017. In 2023, 125 picks gained over 5% and 65 picks gained over 10% in their measured week, with ...

Merck and Moderna are teaming up to make an advanced oncology drug. The candidate's clinical trials are proceeding swimmingly.

In the most recent trading session, Merck (MRK) closed at $107.98, indicating a +0.33% shift from the previous trading day.

Merck remains undervalued with a strong set of growing drugs and new indications in its pipeline. Keytruda has been a major revenue driver for MRK, with continued sales growth and potential for ext...

Merck has managed to thrive throughout its 132-year corporate history. The company posted healthy sales and non-GAAP EPS growth in the third quarter. Merck boasts an A+ credit rating from S&P on a ...

Merck & Co. is a drug manufacturer that has outperformed the healthcare ETF and the S&P 500 over the past decade. The company's pharmaceutical segment, including products like Keytruda and vaccines...

The U.S. Food and Drug Administration (FDA) has declined to approve Merck's drug for chronic cough, the company said on Wednesday, marking the second rejection in less than two years.

Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.

Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.